Safety and tolerability of spesolimab in patients with ulcerative colitis

  • Marc Ferrante (Creator)
  • Peter M. Irving (Creator)
  • Christian P. Selinger (Creator)
  • Geert D' Haens (Creator)
  • Tanja Kuehbacher (Creator)
  • Ursula Seidler (Creator)
  • Savion Gropper (Creator)
  • Thomas Haeufel (Creator)
  • Sebastiano Forgia (Creator)
  • Silvio Danese (Creator)
  • Jochen Klaus (Creator)
  • Geert D' Haens (Creator)

Dataset

Description

Interleukin (IL)-36 signaling has been shown to be increased in ulcerative colitis (UC). Spesolimab, a novel humanized monoclonal antibody, targets the IL-36 pathway. We report safety, immunogenicity, and efficacy data of intravenous (IV) spesolimab in ...
Date made available2022
PublisherTaylor & Francis

Cite this